“…Dundr et al [7] and Li et al [8] report single cases of 1 woman and 1 man with 54 and 61 years of age submitted to radical cystectomy. The former patient was alive at 16 months with lymph node metastasis and the latter was alive without disease at 8 months follow-up.…”
Section: Discussionmentioning
confidence: 99%
“…Primary SCCB is a rare disease that accounts for less than 0.7% of all bladder cancers [29,30]. Primary LCCB is an even rarer disease first described in 1986 [4] and with 17 more cases reported since then [5,6,7,8,9,10,11,12,13,14,15,16]. …”
Section: Discussionmentioning
confidence: 99%
“…Large cell carcinoma of the urinary bladder (LCCB) was first reported in 1986 [4] and since then 17 more cases have been described on the literature [5,6,7,8,9,10,11,12,13,14,15,16]. Because of the relative rarity of these tumors there is no standard approach for managing SCCB [17] or LCCB [13].…”
Introduction: Neuroendocrine carcinomas of the urinary bladder are relatively rare, accounting for less than 1% of all bladder carcinomas. These tumors can be divided into the more indolent typical or atypical carcinoid tumors and the aggressive small cell and large cell neuroendocrine carcinomas. Objective: To report 2 clinical cases of large cell neuroendocrine carcinoma of the bladder (LCCB) and to review the epidemiology, prognosis, and current treatment algorithms for patients with bladder small and large cell neuroendocrine carcinomas. Results: In both cases hematuria was the presenting symptom. One patient was submitted to partial cystectomy and the other to trans-urethral resection of the bladder tumor. The former patient died on the third month postoperatively. The latter patient had extensive liver metastasis at the time of diagnosis and died from acute liver failure on the 14th postoperative day. In review LCCB is associated with a more aggressive behavior and poorer prognosis than transitional cell bladder carcinoma. No standard approach exists. Surgery (transurethral ressection, partial cystectomy, radical cystectomy), chemotherapy and radiotherapy are current treatment modalities. Conclusion: LCCB is an aggressive tumor which usually presents itself in an advanced stage. Neoadjuvant chemotherapy with platinum regimen plus aggressive surgical approach should be the treatment of choice.
“…Dundr et al [7] and Li et al [8] report single cases of 1 woman and 1 man with 54 and 61 years of age submitted to radical cystectomy. The former patient was alive at 16 months with lymph node metastasis and the latter was alive without disease at 8 months follow-up.…”
Section: Discussionmentioning
confidence: 99%
“…Primary SCCB is a rare disease that accounts for less than 0.7% of all bladder cancers [29,30]. Primary LCCB is an even rarer disease first described in 1986 [4] and with 17 more cases reported since then [5,6,7,8,9,10,11,12,13,14,15,16]. …”
Section: Discussionmentioning
confidence: 99%
“…Large cell carcinoma of the urinary bladder (LCCB) was first reported in 1986 [4] and since then 17 more cases have been described on the literature [5,6,7,8,9,10,11,12,13,14,15,16]. Because of the relative rarity of these tumors there is no standard approach for managing SCCB [17] or LCCB [13].…”
Introduction: Neuroendocrine carcinomas of the urinary bladder are relatively rare, accounting for less than 1% of all bladder carcinomas. These tumors can be divided into the more indolent typical or atypical carcinoid tumors and the aggressive small cell and large cell neuroendocrine carcinomas. Objective: To report 2 clinical cases of large cell neuroendocrine carcinoma of the bladder (LCCB) and to review the epidemiology, prognosis, and current treatment algorithms for patients with bladder small and large cell neuroendocrine carcinomas. Results: In both cases hematuria was the presenting symptom. One patient was submitted to partial cystectomy and the other to trans-urethral resection of the bladder tumor. The former patient died on the third month postoperatively. The latter patient had extensive liver metastasis at the time of diagnosis and died from acute liver failure on the 14th postoperative day. In review LCCB is associated with a more aggressive behavior and poorer prognosis than transitional cell bladder carcinoma. No standard approach exists. Surgery (transurethral ressection, partial cystectomy, radical cystectomy), chemotherapy and radiotherapy are current treatment modalities. Conclusion: LCCB is an aggressive tumor which usually presents itself in an advanced stage. Neoadjuvant chemotherapy with platinum regimen plus aggressive surgical approach should be the treatment of choice.
“…The nodes in the ischioanal fossa are at risk for harboring metastases from the cancers of the distal rectum, anal canal, Bartholin's glands, prostate, and urinary bladder. Lymphoma can also cause the lymph nodes to become enlarged in the ischioanal space (3)(4)(5)(6)(15)(16)(17)(18).…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.